Natera price target raised to $185 from $176 at Morgan Stanley

Morgan Stanley analyst Tejas Savant raised the firm’s price target on Natera (NTRA) to $185 from $176 and keeps an Overweight rating on the shares. Q4 revenue came in a touch above the preliminary announcement, while the company’s “prudent” FY25 guidance was “handily above” the Street forecast, but with “ample room for upside” from greater Signatera adoption and prices, biomarker law rollouts, new launches and more, the analyst tells investors. The analyst continues to identify Natera as a “Top Pick.”